{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:42:55Z","timestamp":1792712575066,"version":"4.5.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T00:00:00Z","timestamp":1753920000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD21\/0005\/0004"],"award-info":[{"award-number":["RD21\/0005\/0004"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RD24\/0004\/0024"],"award-info":[{"award-number":["RD24\/0004\/0024"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RICORS2040"],"award-info":[{"award-number":["RICORS2040"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/01351"],"award-info":[{"award-number":["PI20\/01351"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010784","name":"Banco Santander","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010784","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118430","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T16:54:17Z","timestamp":1756832057000},"page":"118430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Subclinical tubular kidney injury associated with immune checkpoint inhibitors and cisplatin treatment: Diagnosis through urinary biomarkers"],"prefix":"10.1016","volume":"191","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8690-446X","authenticated-orcid":false,"given":"Javier","family":"Tasc\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0725-6637","authenticated-orcid":false,"given":"Alfredo G.","family":"Casanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6273-4005","authenticated-orcid":false,"given":"Laura","family":"Vicente-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2540-4461","authenticated-orcid":false,"given":"Marta","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6836-6138","authenticated-orcid":false,"given":"Ana I.","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2025.118430_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00508-017-1285-9","article-title":"Review of cancer treatment with immune checkpoint inhibitors","volume":"130","author":"Thallinger","year":"2018","journal-title":"Wien. Klin. Woche"},{"key":"10.1016\/j.biopha.2025.118430_bib2","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2025.118430_bib3","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1159\/000455014","article-title":"On behalf of cancer and kidney international network workgroup on immune checkpoint inhibitors, adverse renal effects of immune checkpoint inhibitors: a narrative review","volume":"45","author":"Wanchoo","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.biopha.2025.118430_bib4","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.2215\/CJN.00990119","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2025.118430_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004421","article-title":"Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy","volume":"10","author":"Baker","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118430_bib6","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s11096-022-01395-7","article-title":"Sex differences in immune-related adverse events with immune checkpoint inhibitors: data mining of the FDA adverse event reporting system","volume":"44","author":"Chen","year":"2022","journal-title":"Int. J. Clin. Pharm."},{"key":"10.1016\/j.biopha.2025.118430_bib7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40425-018-0478-8","article-title":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience","volume":"7","author":"Mamlouk","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2025.118430_bib8","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3390\/ijms25010414","article-title":"Nephrotoxicity in the age of immune checkpoint inhibitors: mechanisms, diagnosis, and management","volume":"25","author":"Moturi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118430_bib9","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.kint.2019.07.022","article-title":"Immune checkpoint inhibitor nephrotoxicity: what do we know and what should we do?","volume":"97","author":"Perazella","year":"2020","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2025.118430_bib10","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nbt0510-436","article-title":"Next-generation biomarkers for detecting kidney toxicity","volume":"28","author":"Bonventre","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2025.118430_bib11","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1462802","article-title":"Cisplatin-Induced rodent model of kidney injury: characteristics and challenges","volume":"2018","author":"Per\u0161e","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.biopha.2025.118430_bib12","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (Keynote-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2025.118430_bib13","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2025.118430_bib14","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus Gemcitabine\u2013Cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2025.118430_bib15","first-page":"391","article-title":"Ueber den niederschlag, welchen Pikrins\u00e4ure in normalem harn erzeugt und \u00fcber eine neue reaction des kreatinins","volume":"10","author":"Jaffe","year":"1886"},{"key":"10.1016\/j.biopha.2025.118430_bib16","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/clinchem\/21.8.1136","article-title":"New colorimetric reaction for end-point, continuous-flow, and kinetic measurement of urea","volume":"21","author":"Jung","year":"1975","journal-title":"Clin. Chem."},{"key":"10.1016\/j.biopha.2025.118430_bib17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2025.118430_bib18","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1080\/00401706.1972.10488981","article-title":"Extension of sample sizes and percentage points for significance tests of outlying observations","volume":"14","author":"Grubbs","year":"1972","journal-title":"Technometrics"},{"key":"10.1016\/j.biopha.2025.118430_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/B978-012369454-6\/50060-1","article-title":"Clinical chemistry of the laboratory mouse","author":"Quimby","year":"2007","journal-title":"Mouse Biomed. Res."},{"key":"10.1016\/j.biopha.2025.118430_bib20","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jtho.2020.04.021","article-title":"Renal toxicity from pemetrexed and pembrolizumab in the era of combination therapy in patients with metastatic nonsquamous cell NSCLC","volume":"15","author":"Dumoulin","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biopha.2025.118430_bib21","first-page":"457","article-title":"Drug-induced impairment of renal function","author":"Pazhayattil","year":"2014","journal-title":"Int J. Nephrol. Renov. Dis. 7"},{"key":"10.1016\/j.biopha.2025.118430_bib22","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12882-017-0536-3","article-title":"The 6R\u2019s of drug induced nephrotoxicity","volume":"18","author":"Awdishu","year":"2017","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.biopha.2025.118430_bib23","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejim.2023.05.034","article-title":"Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: systematic review and meta-analysis of real-world evidence","volume":"115","author":"Xie","year":"2023","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.biopha.2025.118430_bib24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ejca.2018.07.126","article-title":"The nephrotoxicity of immune checkpoint inhibitor-based combinations","volume":"103","author":"El Rassy","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118430_bib25","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0194599818767621","article-title":"PD-1 inhibition minimally affects Cisplatin-Induced toxicities in a murine model","volume":"159","author":"Spielbauer","year":"2018","journal-title":"Otolaryngol. Head. Neck Surg."},{"key":"10.1016\/j.biopha.2025.118430_bib26","doi-asserted-by":"crossref","first-page":"F626","DOI":"10.1152\/ajprenal.00004.2011","article-title":"Urine albumin as a biomarker in acute kidney injury","volume":"300","author":"Bolisetty","year":"2011","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2025.118430_bib27","series-title":"General Methods in Biomarker Research and Their Applications","first-page":"1","article-title":"Biomarkers in urine and use of creatinine","author":"Tonomura","year":"2014"},{"key":"10.1016\/j.biopha.2025.118430_bib28","doi-asserted-by":"crossref","first-page":"F628","DOI":"10.1152\/ajprenal.00654.2010","article-title":"Renal cortical albumin gene induction and urinary albumin excretion in response to acute kidney injury","volume":"300","author":"Ware","year":"2011","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"10.1016\/j.biopha.2025.118430_bib29","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.3390\/jcm10214942","article-title":"Albuminuria Pre-Emptively identifies cardiac patients at risk of Contrast-Induced nephropathy","volume":"10","author":"Vicente-Vicente","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.biopha.2025.118430_bib30","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.medin.2013.09.001","article-title":"Definici\u00f3n y biomarcadores de da\u00f1o renal agudo: nuevas perspectivas","volume":"38","author":"Seijas","year":"2014","journal-title":"Med. Intensiv."},{"key":"10.1016\/j.biopha.2025.118430_bib31","first-page":"638","article-title":"Early diagnosis of acute kidney injury","volume":"13","author":"Bagshaw","year":"2007","journal-title":"Curr. Opin. Crit. Care"},{"key":"10.1016\/j.biopha.2025.118430_bib32","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bjc.2016.358","article-title":"Acute interstitial nephritis related to immune checkpoint inhibitors","volume":"115","author":"Belliere","year":"2016","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118430_bib33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ckj\/sfw024","article-title":"Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma","volume":"9","author":"Murakami","year":"2016","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.biopha.2025.118430_bib34","article-title":"The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma","volume":"11","author":"Marco","year":"2019","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.biopha.2025.118430_bib35","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1681\/ASN.2019070676","article-title":"Clinical features and outcomes of immune checkpoint Inhibitor\u2013Associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2025.118430_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.574271","article-title":"The use of immune checkpoint inhibitors in oncology and the occurrence of AKI: where do we stand?","volume":"11","author":"Franzin","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2025.118430_bib37","doi-asserted-by":"crossref","unstructured":"D.G. Moledina, F.P. Wilson, J.S. Pober, M.A. Perazella, N. Singh, R.L. Luciano, W. Obeid, H. Lin, M. Kuperman, G.W. Moeckel, M. Kashgarian, L.G. Cantley, C.R. Parikh, Urine TNF-\u03b1 and IL-9 for clinical diagnosis of acute interstitial nephritis, JCI Insight 4 (n.d.) e127456. https:\/\/doi.org\/10.1172\/jci.insight.127456.","DOI":"10.1172\/jci.insight.127456"},{"key":"10.1016\/j.biopha.2025.118430_bib38","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.2169\/internalmedicine.0444-17","article-title":"The analysis of renal infiltrating cells in acute tubulointerstitial nephritis induced by Anti-PD-1 antibodies: a case report and review of the literature","volume":"57","author":"Tabei","year":"2018","journal-title":"Intern Med."},{"key":"10.1016\/j.biopha.2025.118430_bib39","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/967826","article-title":"Pathophysiology of Cisplatin-Induced acute kidney injury","volume":"2014","author":"Ozkok","year":"2014","journal-title":"Biomed. Res. Int."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225006249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T23:22:14Z","timestamp":1778541734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225006249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":39,"alternative-id":["S0753332225006249"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118430","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subclinical tubular kidney injury associated with immune checkpoint inhibitors and cisplatin treatment: Diagnosis through urinary biomarkers","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118430"}}